PDSB — PDS Biotechnology Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1472091 ·
Last close
$0.89
Market Cap
$50.03M
52W High
$1.79
52W Low
$0.19
ADV30
7,075,654
Next earnings
2026-11-13

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -6,496,734 -9,750,575 8,807,213 5,596,254 12,386,952
Mar 2026 0 — -6,521,087 -7,349,056 24,663,026 21,660,496 20,770,383
Dec 2025 0 — -6,674,708 -7,562,919 30,494,083 26,711,969 21,242,250

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,782,788
Investing CF
$0
Financing CF
$-9,494,453
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.71
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-233,706,135
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,014,684
Pretax Income TTM
$-33,671,961
Interest Exp TTM
$6,657,277
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -31,543,959 -34,495,505 30,494,083 21,242,250 9,251,833 -27,752,012
Dec 2024 0 -36,321,195 -37,610,384 45,358,657 26,353,809 19,004,848 -35,030,223
Dec 2023 0 -43,045,234 -42,942,198 59,390,080 33,259,133 26,130,947 -33,636,136
Dec 2022 0 -41,672,421 -40,854,855 77,007,923 33,005,893 44,002,030 -25,709,706

TTM Snapshot

Revenues TTM
$817,987
NetIncome TTM
$-33,671,961
OpCashFlow TTM
—
Assets (Latest)
$8,807,213
Forward EPS
$-0.36

Max Pain — expiry 2027-05-21

max pain strike: $0.50 · spot: $0.78 · call oi: 9,584 · put oi: 1,741
Expected Move to 2027-05-21: ±$0.84 (107.77%) — implied range $-0.06 – $1.63 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ONCY ONCOLYTICS BIOTECH INC $50.15M $0.38 —
APLM Apollomics Inc. $49.09M $16.84 —
HOWL Werewolf Therapeutics, Inc. $51.03M $1.05 —
MIST Milestone Pharmaceuticals Inc. $51.44M $0.41 —
NMAD NOMAD POWER SOLUTIONS, INC. $48.30M $3.00 —

News headlines (Yahoo Finance, 1h cache)

PDS Biotechnology: Q3 Earnings Snapshot
2026-11-13 13:10 · Yahoo
PDS Biotech Reports Third Quarter 2026 Financial Results
2026-11-13 13:00 · Yahoo
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
2026-11-10 13:00 · Yahoo
PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?
2026-11-04 13:55 · Yahoo
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
2026-10-20 12:00 · Yahoo
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer
2026-10-16 01:02 · Yahoo
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
2026-10-14 15:00 · Yahoo
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
2026-10-06 12:00 · Yahoo
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog
2026-09-22 12:00 · Yahoo
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny
2026-09-18 21:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.